Economic Opportunities and Challenges for Pharmacogenomics
- 1 February 2010
- journal article
- review article
- Published by Annual Reviews in Annual Review of Pharmacology and Toxicology
- Vol. 50 (1), 423-437
- https://doi.org/10.1146/annurev.pharmtox.010909.105805
Abstract
Economic evaluation provides health care decision makers with a powerful tool for resource allocation decisions because it offers a framework for comparing the costs and benefits of competing interventions or options. This paper reviews how economic analyses have been applied to the field of pharmacogenomics, both by the pharmaceutical industry to inform investment decisions and by payers to make coverage decisions. There is much anticipation that pharmacogenomic testing is likely to be cost-effective because it uses genomic information to improve drug effectiveness and reduce toxicity both in the drug development process and at the bedside. However, the demonstration of economic benefits first requires that pharmacogenomic testing show evidence of clinical effectiveness. This will only be achieved by greater participation of pharmacogenomics experts in comparative effectiveness research and additional emphasis on including costs in the determination of the relative value of pharmacogenomic testing to the health care system.Keywords
This publication has 38 references indexed in Scilit:
- The Future Costs, Risks and Rewards of Drug DevelopmentPharmacoEconomics, 2009
- Clinically Available Pharmacogenomics TestsClinical Pharmacology & Therapeutics, 2009
- The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIVAIDS, 2008
- Warfarin PharmacogeneticsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2008
- A Case Study of Personalized MedicineScience, 2008
- HLA-B*5701 Screening for Hypersensitivity to AbacavirNew England Journal of Medicine, 2008
- Pharmacoeconomic Evaluations of Pharmacogenetic and Genomic Screening ProgrammesPharmacoEconomics, 2008
- The Challenge of Rising Health Care Costs — A View from the Congressional Budget OfficeNew England Journal of Medicine, 2007
- Can the pharmaceutical industry reduce attrition rates?Nature Reviews Drug Discovery, 2004
- The price of innovation: new estimates of drug development costsJournal of Health Economics, 2003